Skip to main content

Available studies

  • The following is a current list of our open, cancer-related research studies at Virginia Piper Cancer Institute locations, part of Allina Health. Patients can participate in the studies at the locations listed with each study. 

    Breast cancer

    Breast Cancer Registry, Genomic and Quality of Life Studies: 

      • Oncothyreon ONT-380-206 Her2+ Breast Cancer Study
        • Description: Study of ONT-380 vs placebo in combination with capecitabine + trastuzumab in metastatic HER2+ breast cancer - must have prior taxane, trastuzumab, pertuzumab and T-DM1
        • Locations: Abbott Northwestern Hospital, Mercy Hospital – Mercy Campus and Mercy Hospital – Unity Campus
      • Seattle Genetics SGN-LIV1A Study
        • Description: Safety study of SGN-LIV1A in patients with metastatic triple negative breast cancer as a single agent, and ER/PR neg/ Her2 positive metastatic breast cancer with trastuzumab
        • Locations: Abbott Northwestern Hospital, Mercy Hospital – Mercy Campus and Mercy Hospital – Unity Campus
      • CURRENTLY ON HOLD: Gilead GS-US-350-1937 Study
        • Description: A Phase 1b Study Followed by an Open label, Parallel, Randomized Phase 2 Study Evaluating the Safety, Tolerability and Efficacy of GS 5829 in Combination with Exemestane or Fulvestrant Comparing with Exemestane or Fulvestrant Alone in Subjects with Advanced Estrogen Receptor Positive HER2- Breast Cancer 
        • Locations: Abbott Northwestern Hospital, Mercy Hospital – Mercy Campus and Mercy Hospital – Unity Campus
      • MERCK KEYNOTE-355 Triple Negative Breast Cancer
        • Description: Randomized Phase III study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy for previously untreated metastatic triple negative breast cancer
        • Location: Abbott Northwestern Hospital
      • AVAILABLE FOR RURAL PATIENTS: Lally CaringGuidance Study
        • Description: Reducing distress and depressive symptoms in rural women after breast cancer diagnosis: Randomized Controlled Pilot Study
        • Locations: Abbott Northwestern Hospital, Mercy Hospital – Mercy Campus and Mercy Hospital – Unity Campus
        • Contact: Internet-based trial; contact Dr. Robin Lally at 402-559-5464.

      Colorectal cancer

      • BMS CA209-CheckMate 142
        • Description: Phase 2 clinical trial of single agent nivolumab in recurrent and metastatic microsatellite high (MSI-H) Colon Cancer
        • Locations: Abbott Northwestern Hospital and Mercy Hospital – Mercy Campus
      • NORDION TS-102 EPOCH Study
        • Description: A phase III clinical trial evaluating TheraSphere® in patients with metastatic colorectal carcinoma of the liver who have failed first line chemotherapy
        • Location: Abbott Northwestern Hospital

      Cholangiocarcinoma

      • No available trials at this time

      Gastric cancer

      • EMD SERONO 10070-007 First-line Gastric Study
        • Description: Phase III open-label trial of maintenance therapy with avelumab versus continuation of first-line chemotherapy in unresectable, locally adv/met cancer of stomach or G-E junction
        • Locations: Abbott Northwestern Hospital and Mercy Hospital – Mercy Campus and Mercy Hospital – Unity Campus

      Glioblastoma

      • No available trials at this time

      Gynecology cancers (cervical and ovarian cancer)

      • AZ LIGHT Ovarian Cancer Study
        • Description: Open-label Phase II study to assess olaparib tablets for patient with different HRD tumor status, platinum-sensitive, relapsed ovarian, fallopian tube or primary peritoneal cancer that have had at least 2 prior lines of chemotherapy
        • Location: TBD

      Head and neck cancer

      • Aspyrian RM-1929/101 Head & Neck Cancer Study
        • Description: Early phase I study of RM-1929 (study drug) and photoimmunotherapy in patients with recurrent Head & Neck cancer
        • Location: Abbott Northwestern Hospital 
      • CALM Acupuncture Study
        • Description: Pilot RCT to assess feasibility, symptoms and biobehavioral outcomes of acupuncture in patients undergoing radiation therapy for squamous cell cancer of the head & neck.
        • Location: Abbott Northwestern Hospital 

      Hematology

      • No available trials at this time

      Hepatobiliary cancer

      • Mayo Hepatobiliary Registry and Biorepository
        • Description: International registry of hepatobiliary cancers including hepatocellular carcinoma, cholangiocarcinoma, and gallbladder adenocarcinoma, and unaffected individuals. 
        • Locations: Abbott Northwestern Hospital and Mercy Hospital – Mercy Campus

      Lung cancer

        • Genomic Health 14-009 Liquid Biopsy Study
          • Description: A Study To Determine the Concordance of Key Actionable Genomic Alterations as Assessed in Tumor Tissue and Plasma From Patients with Non Small Cell Lung Carcinoma (NSCLC)
          • Locations: Abbott Northwestern Hospital, Mercy Hospital – Mercy Campus and Mercy Hospital – Unity Campus

        Lymphoma/Leukemia

        • Cantex CX-01 AML Study
          • Description: Randomized Phase II study CX-01 (3 different dose levels) + standard induction therapy for newly diagnosed AML 
          • Locations: Abbott Northwestern Hospital and Mercy Hospital – Mercy Campus

          Melanoma

          • Amgen 139 Talimogene Laherparepvec (T-VEC) Registry
            • Description: Registry study for patients who have previously received T-VEC
            • Location: Mercy Hospital – Mercy Campus
          • Amgen T-VEC 265 MASTERKEY-265
            • Description: Phase 3 study of T-VEC + pembrolizumab for unresected, stage IIIB to IVM1c melanoma 
            • Location: Mercy Hospital – Mercy Campus
          • BMS CA-209-915 Adjuvant Melanoma Study
            • Description: Phase 3 RCT of adjuvant nivolumab + ipi versus ipi or nivolumab monotherapy after complete resection of stage IIIb/c/d or stage IV melanoma
            • Locations: Abbott Northwestern Hospital and Mercy Hospital – Unity Campus
          • Takeda C28003 Melanoma Study
            • Description: Phase Ib study to evaluate the safety and response rate of TAK-202 + nivo or vedolizumab + nivo + ipi in patients with advanced melanoma
            • Locations: Abbott Northwestern Hospital and Mercy Hospital – Mercy Campus

          Multiple myeloma

          • No available trials at this time

          Ovarian cancer

          See Gynecology cancers

          Pancreatic cancer

          • HALOZYME HALO 109-301
            • Description: Phase 3 RCT of Gem/Abraxane + PEGylated recombinant Human Hyaluronidase (PEGPH20)/Placebo for HLA-high Stage IV previously untreated pancreas cancer 
            • Locations: Abbott Northwestern Hospital, Mercy Hospital – Mercy Campus and Mercy Hospital – Unity Campus
          • ARMO AM0010-301 ARTIST 1 Pancreas Cancer Study
            • Description: Randomized phase 3 study of AM0010 + FOLFOX vs. FOLFOX alone as second-line therapy for metastatic pancreatic cancer that has progress after a first-line gemcitabine-containing regimen
            • Location: Abbott Northwestern Hospital
          • University of Minnesota Tissue Procurement Study
            • Description: Development of Oncolytic Adenovirus targeting cancer stem cells: Tissue procurement study from pancreatic or esophageal cancer surgery (Kamath/Kelsey 863-8716)
            • Location:  Abbott Northwestern Hospital
          • PCRT 15-001 Project Survival Study
            • Description: Collection of blood, urine, and saliva to identify and validate biomarkers for early detection and treatment of pancreatic diseases, including adenocarcinoma and pancreatitis (Kamath/Kelsey 863-8716) 
            • Location: Abbott Northwestern Hospital
          • Pancreatic Screening
            • Description: Registry Study to Determine the Utility and Feasibility of a Pancreatic Cancer Screening Program for Patients at High Risk of the Disease Based on Genetics and Family History (Rossi/Kelsey 863-8551)
            • Location: Abbott Northwestern Hospital 

          Renal cell cancer

          • No available trials at this time

          Solid tumor

          • No available trials at this time

          Urothelial cancer

          • No available trials at this time
        • Contact us

          Call 612-863-8716.

          800 E. 28th St.
          Minneapolis, MN 55407

          Research program leaders